What is HC Wainwright’s Forecast for Evotec FY2024 Earnings?

Evotec SE (NASDAQ:EVO) – Stock analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Evotec in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.51) per share for the year, down from their previous estimate of ($0.42). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Evotec’s Q4 2024 earnings at ($0.04) EPS, FY2026 earnings at $0.23 EPS and FY2027 earnings at $0.47 EPS.

Several other research firms have also recently weighed in on EVO. Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.70 to $3.80 in a research report on Monday, October 7th. Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Evotec has an average rating of “Hold” and an average target price of $5.93.

Evotec Stock Down 2.8 %

Evotec stock opened at $4.13 on Monday. The stock has a 50-day simple moving average of $3.51 and a 200 day simple moving average of $4.20. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42. Evotec has a 12-month low of $2.85 and a 12-month high of $12.00.

Institutional Trading of Evotec

Several institutional investors and hedge funds have recently made changes to their positions in the business. Novo Holdings A S bought a new stake in shares of Evotec in the 2nd quarter valued at about $71,183,000. Cetera Advisors LLC bought a new stake in Evotec in the first quarter valued at approximately $188,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Evotec in the second quarter worth $87,000. DCF Advisers LLC boosted its position in shares of Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the 3rd quarter valued at $512,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.